Gut Metabolisation Test

Relative abundance of bacterial genera in CCOS GMT

The Gut Metabolisation Test (GMT) from CCOS allows the determination of faecal degradation of drugs in vitro in the field of drug metabolism and pharmacokinetics (DMPK). The GMT can be used to evaluate drug candidates during the early development phase.

Add your compound in micromolar range to our standardized and safe human faecal homogenate and measure samples up to 240 minutes to calculate the half-life and check for metabolites or toxic by-products by e.g. UPLC-MS. With this data you will get information about the degradation of your drugs by human gut bacteria.

The human gut microbiome has an effect on the metabolism of drugs. Orally administrated drugs could be converted by the gut microflora into compounds which are therapeutically ineffective or toxic to patients. In addition, prodrugs could be converted into their active form.

The gut microbiota encodes a broad range of enzymes that have been shown to be responsible for biochemical modification of drugs through reduction, hydrolysis, acetylation, dehydroxylation, demethylation, deamination or deconjugation.

The CCOS Gut Metabolisation Test is composed of pooled and homogenised faecel samples from healthy volunteers, that have signed a declaration of consent for the usage of the samples. All volunteers were tested serological for the absence of HIV, HAV, HBV, HCV and EBV. In addition, the pooled samples were tested microbiologically for the absence of Salmonella and the composition of the bacterial and fungal microbiome was determined by next generation sequencing techniques.

The metabolic activitity of the Gut Metabolisation Test was verified with the following assays: decolorisation of gentian violet, β-glucuronidase activity, reduction of sulfozalazine.

The GMT is available as frozen samples (-80°C) in two sizes: 0.5 ml and 4 ml.